#news #biotech Teva scraps Heptares migraine pact as lead drug nears clinic

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Teva scraps Heptares migraine pact as lead drug nears clinic .Teva has pulled out of a migraine R&D pact with Sosei’s Heptares. The Israeli pharma, which paid $10 million (€8 million) and committed to up to $400 million in milestones in 2015 to collaborate with Heptares on CGRP antagonists, bailed before the first program hit the clinic.

from FierceBiotech: Biotech http://ift.tt/2Hu9Ioy